Curve Biosciences, the Whole-Body Intelligence™ company, announced it has raised $40 million in Series A funding led by Luma Group, with participation from First Spark Ventures, Techas Capital, Civilization Ventures, LifeX Ventures, and others. The funding will be used to accelerate the clinical validation and commercialization of its platform for chronic disease monitoring.
Addressing the growing costs and prevalence of chronic diseases, Curve Biosciences emphasizes that improved patient monitoring is essential to maximize the benefits of modern medical breakthroughs such as GLP-1s. The company has developed the Whole-Body Atlas™, described as the world’s largest collection of manually curated tissue samples categorized by organ and disease state. By returning to this tissue-level biological foundation, Curve is creating Whole-Body Blood Tests™ powered by its Whole-Body Intelligence platform. These tests are designed to anticipate chronic disease, guide treatment decisions, and align patients, insurers, pharmaceutical companies, and healthcare providers.
“To raise the standard of chronic disease monitoring, we are now introducing the first Whole-Body Intelligence platform with AI models trained on our Whole-Body Atlas and fueled by our Whole-Body Blood Tests,” said Ritish Patnaik, PhD, CEO and Co-Founder of Curve Biosciences.
The company’s leadership team brings extensive expertise in blood testing and precision medicine. CEO Ritish Patnaik, PhD, formerly led business development at Genentech, focusing on AI, data engineering, and precision testing. Chief Scientific Officer Nathan Hunkapiller, PhD, previously served as Head of R&D at Natera and GRAIL, where he developed advanced blood tests for oncology and prenatal screening. Chief Operating Officer Alice Chen, PhD, was Head of Product and Program Management at GRAIL, leading strategy for a multi-cancer early detection blood test. Chief Technology Officer Chuba Oyolu, PhD, was a Founding Scientist and Senior Site Director at Counsyl, with expertise in scaling advanced blood tests. Chief Innovation Officer Prof. Shan Wang, PhD, is the Leland T. Edwards Professor at Stanford University, credited with more than 300 publications and over 70 patents.
Click here to read the original news story.